Recent studies of knockout mice conclusively show that the mu opioid receptor mediates the analgesic effects of morphine; they further suggest that the mu opioid receptor also has a role in mediating the effects of other opioid agonists, and provide insights into the non-analgesic effects of mu opioids.
Morphine, as derived from the opium poppy, has been used in the treatment of pain and dysentery, and for its euphoric properties, for thousands of years. Sir William Osler referred to morphine as "God's own medicine", and morphine is still a drug of choice in the treatment of severe pain. Indeed, morphine remains the standard by which new analgesics are measured. The identification of the molecular target of morphine is, therefore, an important research goal. Several decades of pharmacological research pointed to the mu opioid receptor as the principal target for morphine actions, but the recent development of opioid receptor knockout mice has provided exciting new tools to confirm this identity and to explore the normal physiological functions of opioid receptors.
The application of molecular biological techniques to the study of opioid receptors has gratifyingly given results that closely parallel the traditional pharmacological data. Opioid receptors, which are known to signal by coupling to G proteins, have traditionally been grouped into three major classes -mu, delta and kappa. This subdivision has been supported by the results of cloning and analyzing the receptor-encoding genes. First to be cloned was the delta receptor gene, quickly followed by the genes for the mu and kappa receptors, as well as for a related 'orphan' receptor variously named ORL1 or KOR-3 (reviewed in [1] ). These receptors turn out to be closely related in sequence, the seven transmembrane regions characteristic of G-coupled receptors being especially similar. Interestingly, although pharmacological data suggest the major classes of opioid receptors can be subdivided into several subtypes, no evidence for separate opioid receptor subtype genes has come from the molecular data.
Although pharmacological studies have suggested that mu opioid receptors mediate the neuronal and non-neuronal effects of morphine, the ability to 'knockout' the cloned receptor genes in mice by targeted recombination in embryonic stem cells offers a powerful new way of investigating the physiological and pharmacological roles of the opioid receptors. In the past year, several of these mutant mice with inactivated opioid receptor genes have been generated, with the most information so far coming from studies of mice that lack mu opioid receptors. The construction of these knockout mice depended upon cloning and sequencing of the entire opioid receptor gene [2] , and was first reported by Matthes et al. [3] and Sora et al. [4] .
The knockout mice show clear clear effects of lacking functional mu opioid receptors. In all cases examined, effects previously defined as mu-receptor-mediated are abolished in the homozygous mutant mice. For example, ligand binding to mu receptors, assayed either in membranes or in brain sections by autoradiography, was reduced by approximately 50% in the heterozygous mice and was undetectable in the homozygous mice. But, in the mutant mice, no changes could be detected in binding of ligands specific for delta or kappa receptors, or in the levels of mRNAs encoding precursor proteins -pro-enkephalin, pro-dynorphin and pro-opiomelanocortin -from which endogenous opioid peptides are naturally derived. Most importantly, the actions of morphine in a variety of assay systems were eliminated in the homozygous mu receptor mutant mice (Table  1 ). In particular, acute morphine analgesia, as determined in a variety of tests, was eliminated. Similarly, the production of withdrawal symptoms following chronic morphine treatment, and the reinforcing effects of morphine as determined in conditioned place preference tests, were also eliminated in the mu receptor knockout mice.
To opioid pharmacologists all over the world, these results were both comforting and somewhat surprising. For many years, pharmacological assays -both in vivo and in vitro -have suggested that morphine's principal biological actions occur through mu opioid receptors, and the elimination of morphine effects in mu receptor mutants confirms this pharmacological evidence in a satisfyingly conclusive manner. The pharmacological evidence also indicated, however, that morphine is not highly selective in binding to mu receptors rather than delta and kappa receptors; in fact, morphine is only 40 times more potent at mu receptors than at delta receptors. It was somewhat surprising, therefore, that no deltareceptor-mediated effects were observed in the mu receptor mutant mice at high morphine doses. This result could be explained by the attenuation of delta-receptorselective analgesia in the mu receptor mutants (see below), or if the morphine doses were not high enough to cause significant delta receptor activation in these mice.
Although the effects of morphine itself appear to be eliminated in mu knockout mice, recent results of Schuller et al. [5] suggest that some effects of opioids that were previously thought to be mu-receptor-mediated may be mediated by other receptors. Traditional pharmacological evidence has long suggested that the actions of the heroin are caused by deacetylation of heroin to form morphine in the brain, where it acts at mu receptors. However, recent studies have shown that heroin and morphine analgesia are blocked by different antisense oligonucleotides to the mu receptor [6] . Interestingly, in the mu receptor knockout mice, where morphine analgesia is eliminated, heroin analgesia is only partially attenuated [5] . The authors infer from their results the existence of a distinct heroin receptor, which must be related structurally to the mu receptor given that the antisense oligonucleotides that blocked heroin analgesia were based on the nucleotide sequence that encodes the mu receptor.
These results present an interesting paradox, however. If the heroin receptor is a product of the mu receptor gene, then how can heroin analgesia be maintained in a knockout mouse that lacks a functional mu receptor gene? Schuller et al. [5] suggest that alternative splice variants of the mu receptor mRNA -the existence of which is a distinct possibility because of the existence of several introns within the coding region of the mu receptor gene -may still be produced in the mu receptor knockout mice. This conclusion is likely to be controversial, as the presence of opioid receptor splice variants has been difficult to confirm directly. Future examination of heroin effects in mu knockout mice from different laboratories -especially where the knockouts were prepared by manipulating different parts of the mu receptor gene -should help to clarify this puzzling issue.
Interesting effects have been observed in mice that are heterozygous for a targeted mutation of the mu receptor gene, mice that make half of the normal complement of mu receptors (G.R. Uhl, personal communication). Whereas the homozygous mutant mice displayed no detectable effects of morphine in a variety of tests, the heterozygous animals displayed increased morphine reinforcement (as determined by conditioned place preference), and unchanged levels of physical dependence and morphine tolerance compared to wild-type mice. The various physiological effects of morphine are, therefore, not each related in a stoichiometric way to the number of mu receptors. Although there are several possible explanations for these differences, Uhl and colleagues favour the view that they are indicative of the different receptor levels -that is, the receptor reserve -required for the various different physiological effects of morphine.
What are the effects of mu receptor deficiency on the physiological actions mediated by other opioid receptor types? The answer is also somewhat surprising. Studies of delta opioid analgesia, using the delta-selective analogs BUBU [3] and DPDPE [7] , revealed that delta analgesia was, like morphine analgesia, profoundly reduced in the mu receptor knockout mice (Table 1) . This is confusing, as receptor binding data clearly showed that delta receptors are expressed normally in the mu receptor mutants, at least in some brain regions. These results may indicate that neuronal circuits employing mu receptors have a role in delta analgesia, as suggested by Sora et al. [7] . Interestingly, preliminary results (B. Kieffer, personal communication) show that the efficacy of delta receptor coupling to G proteins may be reduced in the spinal cord of mu receptor knockout mice, suggesting that lack of mu receptors may affect the functioning of the delta opioid system without any discernible change in the number of delta receptors themselves.
An important question that can be addressed in opioid receptor knockout mice is the role of the receptors in normal -non-drug-induced -physiology and behavior. In analgesia testing, the mu receptor mutants displayed decreased baseline latencies in 'tailflick' assays, suggesting increased nociception (pain) sensitivity [4] . In addition to their role in mediating analgesia, mu receptors have long been implicated in other processes, such as gastrointestinal motility, respiratory control, motor activity and hormonal regulation. As mentioned above, the mu knockout mice did not exhibit any major developmental defects. In a recent study by Tian et al. [8] , however, several other parameters appeared to be altered in these mutant mice. For example, the homozygotes showed reduced locomotor R696 Current Biology, Vol 7 No 11 Table 1 Physiological effects of mu opioid receptor deficiency.
Measure Effect Reference
Morphine* analgesia Blocked [3, 4] Morphine reinforcement † Blocked [3] Chronic morphine tolerance Blocked [3] Chronic morphine withdrawal Blocked [3] DPDPE, BUBU ‡ analgesia Blocked [3, 7] Heroin analgesia Partial reduction [5] Basal nociception Increased [4] Basal locomotor activity Decreased [8] Basal sexual activity Decreased [8] Immune cell activity Increased [8] *Morphine is considered to be a mu-receptor-specific agonist. † This is based on a conditioned place preference test. ‡ DPDPE and BUBU are thought to be delta-receptor-specific agonists.
activity compared to wild-type, and the increase in motor activity normally observed after administration of morphine was not evident in the knockout mice. These effects are not surprising, considering the relatively high density of mu opioid receptors in the striatum, a brain area known to be important in regulating motor activity.
Other abnormalities of the mu knockout mice were surprising, however, especially changes in sexual behavior (the level of which was unusually low in the mutants) and in immune responses (the proliferation of immune progenitor cells was increased in the mutants). As in any work with knockout mice, these conclusions must be tempered by the possibility that the results may be influenced by non-specific adaptive changes caused by inactivation of the mu receptor gene. Nevertheless, these results demonstrate how transgenic methodologies have the potential to reveal physiological roles of receptors that may not have been predicted from standard pharmacological approaches.
At the recent International Narcotics Research Conference (Hong Kong, August, 1997), several groups reported preliminary data on the effects of opioids in knockout mice lacking either delta or kappa opioid receptors. In delta receptor knockout mice (J. Pintar, personal communication), the effects on delta-mediated analgesia depended upon the route of drug administration: intra-cerebral, but not spinal, delta analgesia was maintained in the delta knockout animals. These results point out the important differences that have often been noted about mechanisms of analgesia, depending upon the route and dose of agonist administration. In kappa receptor knockout mice (B. Kieffer, personal communication), kappa, but not morphine, analgesia was blocked. Interestingly, the kappa knockout mice also displayed increased baseline pain in a writhing test, suggesting that kappa receptors may have a role in modulating intrinsic pain sensitivity.
Future studies with other receptor knockout mice may reveal other interesting aspects of opioid action. For example, at the conference in Hong Kong, results presented by R. Maldonado (University René Descartes, Paris) showed significant alterations in opioid effects in dopamine D 2 receptor knockout mice. While morphine analgesia appeared normal in these mice, morphine reinforcement was significantly attenuated in the D 2 homozygous animals. If these preliminary results are confirmed, then they would provide important direct evidence for the role of dopaminergic systems in mediating opioid reward mechanisms.
In summary, several points can be made about this first round of data from opioid receptor knockout mice. First, and most important, most of the studies are still at an early stage, and conclusions will undoubtedly be affected by a number of factors, including the genetic backgrounds of the knockout mice, the methods of biological testing, and the routes of administration of test drugs. For these reasons, discrepancies between laboratories are to be expected. The conclusions must also be cautious because of the real possibility of non-specific neuroadaptive changes that may occur in response to the loss of a specific gene throughout development. In future, the development of conditionally-deficient knockout mice will help to address this important issue. In the meantime, while the opioid receptor knockout mice have clearly determined the site of action of one opioid drug -morphine -they have brought into question the role of specific opioid receptors in mediating other opioid effects, and opened new areas of speculation about the role of these receptors in mediating normal physiological functions.
